海南重大新药创制成果转化战略选择与对策

The Strategic Choice and Countermeasures of the Transformation of New Drug Development in Hainan Province

海南自由贸易港建设为海南新药创制带来了机遇和挑战。首先通过构建CLAP-SWOT模型系统分析了海南新药创制成果转化的内在优劣势及外部机遇与挑战,指出企业存在资产负债率低、现代药物制剂聚集等优势条件,并面临自由贸易港建设的重大机遇,但也存着技术合同交易总量低、产业结构单一等劣势,同时面临创新环境不足等挑战;然后将定量战略计划矩阵与SWOT联用,判断海南中医药细分领域处在SO区域,医疗器械细分领域尚处在WO区域,应采取中医药领域产业链创新链融合,医疗器械领域加大科技投入引导突破性成果产出的战略。最后,提出海南新药创制成果转化的政策建议,包括强化企业创新主体地位、主动布局大健康产业、支持高水平创新创业、搭建成果转化政策服务平台等。

The construction of Hainan Free Trade Port brings some opportunities and challenges for the new drug development in Hainan. In this paper, the CLAP-SWOT model is constructed to analyze the inherent advantages and the external opportunities and challenges in the transformation of new drug development in Hainan. For one thing, in face of the important opportunity of building the free trade port, there exist such advantages as the low asset liability ratio of corporations, and the concentration of modern pharmaceutical preparations and so on. For another, the total amount of technology contract transactions is low, the industrial structure single, and the innovation environment insufficient. Furthermore, the quantitative strategic planning matrix and SWOT are mutually employed to classify the subdivision of Hainan’s traditional Chinese medicine into the SO region, and the subdivision of medical facilities into the WO region. Hence it is suggested that the integration strategy of industry chain and innovation chain be adopted in the field of traditional Chinese medicine, and the scientific and technological inputs be enlarged to elicit the outputs of breakthrough achievements in the field of medical facilities. Finally,some policy suggestions are put forward for the transformation of new drug development in Hainan, such as strengthening the dominant position of enterprises in innovation, planning the big health industry initiatively,supporting the high-level innovation and entrepreneurship, and building a policy service platform for achievement transformation.